Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Med LifeLTS:0RO5 70 5-Year Yield-on-Cost % is 0.00 as of Jul. 20, 2026. GuruFocus rates LTS:0RO5 with a GF Score™ of 70/100 and a GF Value™ of lei1.40 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 279 Healthcare Providers & Services companies, Med Life ranks worse than 358422.58% on this metric.
Med Life's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Med Life's 5-Year Yield-on-Cost % or its related term are showing as below:
LTS:0RO5's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.93 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Med Life (LTS:0RO5) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Med Life 5-Year Yield-on-Cost % Related Terms
LTS:0RO5 vs HCA, THC, DVA: 5-Year Yield-on-Cost % Comparison
For the Medical Care Facilities subindustry, Med Life's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Med Life 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Med Life's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Med Life's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Med Life is calculated as
Med Life (LTS:0RO5) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 20, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Med Life and its competitors. According to the industry distribution chart, Med Life ranks #999999 out of 279 companies in the Healthcare Providers & Services industry.
Is Med Life's 5-Year Yield-on-Cost % too high?
Med Life's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Med Life ranks #999999 out of 279 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Med Life has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's 5-Year Yield-on-Cost % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #999999 out of 279 companies for 5-Year Yield-on-Cost %. This places Med Life in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.93, based on 279 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Med Life and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei1.40, compared to a current price of lei11.38 — trading 712.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Med Life's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (LTS:0RO5) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.38 is trading 712.5% above its estimated GF Value™ of lei1.40.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for LTS:0RO5:
5-Year Yield-on-Cost %: 0.00
GF Value™: lei1.40 vs. price of lei11.38 (712.5% above fair value)
No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
70GF Score
Get the complete analysis for LTS:0RO5
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RO5 has been successfully added to your 
